Скачать или смотреть PROMETICO presents novel insights into metastatic colorectal cancer

Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain presents findings from PROMETICO (NCT03935763), the first international prospective real world-study evaluating patients with metastatic colorectal cancer after two disease progressions, including patients with ECOG performance status (PS) of 2, a subgroup typically excluded from clinical trials. TAS-102 was the most frequently used regimen, and higher adverse event rates, such as anemia, reflected more advanced disease progression. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.